CompletedNCT04112368
Hormone Cycles, Arousal and Short-Term Suicide Risk
About this title
Read the official source — NCT04112368Medication studyAges 18–45United StatesSuicide prevention
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- ChicagoSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: September 15, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 124
- Sponsor
- University of Illinois Chicago
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT04112368
- Official title
Show the full official title
Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Chicago
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Illinois Chicago, a university.
Did this study involve medication?
Yes. The study involved medication, including Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone 200mg, Inactive Clear Patch and Placebo capsule.
Who was this study for?
Listed age limits: 18 years to 45 years.
